Social network
  • Visit We R Hope page

    We R Hope by Sanofi

  • Fighting dengue ferver

    Fighting dengue ferver

  • Meet Anne-Olivier Bandini: R&D Team Leader, France

  • Isabelle, Type 1 diabetes, France

    Isabelle, Type 1 diabetes, France

    Tools content (print, share, increase/decrease text size):

     

    Clinical Study Results - Sanofi Pharma, including Sanofi Genzyme

    Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available.  Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.

    This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

    A

    Letter A
    Generic NameTrade NameConditionStudy CodeStudy NameAccess to studyAccess to results
    AFLIBERCEPTZaltrapCancerTES10897QUTIENCT00876044
    AFLIBERCEPTZaltrapCancerARD6122NANCT00327171
    AFLIBERCEPTZaltrapCancerARD6123NANCT00284141
    AFLIBERCEPTZaltrapCancerEFC6125NANCT00327444
    AFLIBERCEPTZaltrapCancerEFC6546NANCT00519285
    AFLIBERCEPTZaltrapCancerARD6772NANCT00396591
    AFLIBERCEPTZaltrapCancerEFC10262VELOURNCT00561470
    AFLIBERCEPTZaltrapCancerEFC10261VITALNCT00532155
    AFLIBERCEPTZaltrapCancerEFC10547VANILLANCT00574275
    AFLIBERCEPTZaltrapCancerEFC10668AFFIRMNCT00851084
    AFLIBERCEPTZaltrapCancerEFC10668AFFIRMNCT00851084
    AFLIBERCEPTZaltrapCancerTCD11382NANCT01148615
    AFLIBERCEPTZaltrapCancerTCD11470NANCT01930552
    AFLIBERCEPTZaltrapColorectal cancerAFLIBC06561AMORNCT01955629
    AFLIBERCEPTZaltrapCancerTCD6117NANA
    AFLIBERCEPTZaltrapColorectal cancerEFC11338AFLAMENCT01661270
    AFLIBERCEPTZaltrapNon Hodgkins LymphomaTCD10173NANCT00644124
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-005-99NANCT00074971
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-006-99*NA
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-007-99*NA
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-008-00NANCT00074984
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-016-01NANCT00074958
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-017-01NANCT00196716
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-019-01*NA
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-022-02NANCT00837824
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL02503NANCT00081497
    AGALSIDASE BETAFabrazymeFabry DiseaseAGAL-1-002-98*NA
    AGALSIDASE BETAFabrazymeFabry DiseaseFB9702-01*NA
    ALEMTUZUMABCampathLeukemiaCAM211*NA
    ALEMTUZUMABCampathLeukemiaCAM307*NANCT00046683
    ALFUZOSINUroxatral, XatralProstatic DiseasesALFUS_L_01241SAMBA_THAILANDNCT00401661
    ALFUZOSINUroxatral, XatralProstatic DiseasesALFUS_L_01667SAMBANCT00486785
    ALFUZOSINUroxatral, XatralBenign Prostatic HyperplasiaDRI5234NANCT00409357
    ALFUZOSINUroxatral, XatralBenign Prostatic HyperplasiaEFC4428ALFAURUSNCT00290030
    ALFUZOSINUroxatral, XatralBenign Prostatic HyperplasiaEFC4485NANCT00029822
    ALFUZOSINUroxatral, XatralNeurogenic Urinary BladderEFC5722ALPHACHINNCT00549939
    ALFUZOSINUroxatral, XatralBenign Prostatic HyperplasiaEFC5791NANCT00399464
    ALFUZOSINUroxatral, XatralHydronephosis Neurogenic BladderEFC6269ALPHAHYDRONCT00576823
    ALFUZOSINUroxatral, XatralProstatic DiseasesL_8472ALF-ACUTENCT00540891
    ALFUZOSINUroxatral, XatralProstatic DiseasesL_8758NANCT00637715
    ALFUZOSINUroxatral, XatralProstatic DiseasesL_8819NANCT00542165
    ALFUZOSINUroxatral, XatralProstatic DiseasesL_8935ALEX-XLNCT00575913
    ALFUZOSINUroxatral, XatralUrologic DiseasesL_9397ALF-RIKNCT00453908
    ALFUZOSINUroxatral, XatralProstatic DiseasesL_9645NANCT00336921
    ALFUZOSINUroxatral, XatralCalculiL_9795ALF-STONENCT00454402
    ALFUZOSINUroxatral, XatralBenign Prostatic HyperplasiaLTS5235NANCT00347061
    ALFUZOSINUroxatral, XatralUrinary Bladder NeurogenicPKM6270ALPHACHIPNCT00629720
    ALFUZOSINUroxatral, XatralProstatic DiseasesPM_L_0168ALFONE CHINANCT00280605
    ALGLUCOSIDASE ALFAMyozymePompe DiseaseAGLU01602NANCT00059280
    ALGLUCOSIDASE ALFAMyozymePompe DiseaseAGLU01702NAEudraCT: 2004-002168-59
    ALGLUCOSIDASE ALFAMyozymePompe DiseaseAGLU02804NAEudraCT: 2005-002829-31
    ALIROCUMABPraluentHypercholesterolemiaDFI11565NANCT01288443
    ALIROCUMABPraluentHypercholesterolemiaDFI11566NANCT01288469
    ALIROCUMABPraluentHypercholesterolemiaDFI12361NANCT01812707
    ALIROCUMABPraluentHypercholesterolemiaEFC11568ODYSSEY COMBO INCT01644175
    ALIROCUMABPraluentHypercholesterolemiaEFC11569ODYSSEY COMBO IINCT01644188
    ALIROCUMABPraluentHypercholesterolemiaEFC11716ODYSSEY MONONCT01644474
    ALIROCUMABPraluentHypercholesterolemiaEFC12492ODYSSEY FH INCT01623115
    ALIROCUMABPraluentHypercholesterolemiaEFC12732ODYSSEY HIGH FHNCT01617655
    ALIROCUMABPraluentHypercholesterolemiaEFC13672ODYSSEY JAPANNCT02107898
    ALIROCUMABPraluentHypercholesterolemiaLTS11717ODYSSEY LONG TERMNCT01507831
    ALIROCUMABPraluentHypercholesterolemiaPOP12671NANCT01670734
    AMIBEGRONNot marketedMajor Depressive DisorderEFC4846ZEPHIRNCT00319709
    AMIBEGRONNot marketedMajor Depressive DisorderEFC5041ORIONNCT00252356
    AMIBEGRONNot marketedMajor Depressive DisorderEFC5116PHOENIXNCT00252330
    AMIBEGRONNot marketedMajor Depressive DisorderEFC5374NANCT00825058
    AMIBEGRONNot marketedMajor Depressive DisorderEFC5379NANCT00825019
    AMIBEGRONNot marketedGeneralized anxiety disorderEFC5891ELECTRANCT00332891
    AMIBEGRONNot marketedGeneralized anxiety disorderEFC5892LIBRANCT00252343
    AMIBEGRONNot marketedGeneralized anxiety disorderEFC5893AQUARIUSNCT00266747
    AMIBEGRONNot marketedGeneralized anxiety disorderEFC5895GEMININCT00535340
    AMIBEGRONNot marketedMajor Depressive DisorderEFC6224ALBERIONCT00432614
    AMIBEGRONNot marketedMajor Depressive DisorderEFC6607SIRIUSNCT00385307
    AMIBEGRONNot marketedMajor Depressive DisorderLTE5376CALYPSONCT00345098
    AMIBEGRONNot marketedGeneralized anxiety disorderLTE5894VEGANCT00397098
    AMIBEGRONNot marketedMajor Depressive DisorderLTS4848NANCT00855530
    AMISULPRIDESolianSchizophreniaAMISU_L_01008AMIMINDNCT00761670
    AMISULPRIDESolianBipolar DisorderC_8428SOLMANIANCT00126009
    AMISULPRIDESolianSchizophreniaL_8967AMIRISMINDNA
    AMISULPRIDESolianSchizophreniaL_8968NANCT00331981
    AMISULPRIDESolianSchizophreniaL_9517ASAPNCT00436371
    AMISULPRIDESolianSchizophreniaPM_L_0055SOLIACSNCT00245674
    AMISULPRIDESolianSchizophreniaAMISUL06155ESCAPENCT01795183
    ANTI-PNAG MONOCLONAL ANTIBODYNot marketedInfection prophylaxisPKD11791NANCT01389700
    ANTI-THYMOCYTE GLOBULIN (RABBIT)Thymoglobulinkidney transplant rejectionSANG-93-3-K-THY-R*NA
    ANTI-THYMOCYTE GLOBULIN (RABBIT)Thymoglobulinkidney transplant rejectionSANG-96-3-K-THY-I*NA
    ANTI-THYMOCYTE GLOBULIN (RABBIT)Thymoglobulinkidney transplant rejectionSMC-101-1002*NA
    ANTI-THYMOCYTE GLOBULIN (RABBIT)Thymoglobulinkidney transplant rejectionSMC-101-1007*NA
    ANTI-THYMOCYTE GLOBULIN (RABBIT)Thymoglobulinkidney transplant rejectionSMC-101-1008*NA
    ANTI-THYMOCYTE GLOBULIN (RABBIT)Thymoglobulinkidney transplant rejectionSMC-101-1009*NA
    ANTI-THYMOCYTE GLOBULIN (RABBIT)Thymoglobulinkidney transplant rejectionSMC-534-1003*NA
    ARTESUNATEArsucamMalariaARTEN_L_00848ACT MALINCT00452907
    ARTESUNATEArsucamMalariaPM_L_0163ATOLNCT00445796
    ARTESUNATE + AMODIAQUINECoarsucamMalariaARAMF_L_01570NANCT00386503
    ARTESUNATE + AMODIAQUINECoarsucamMalariaARAMF_L_02873NANCT00540410
    ARTESUNATE + AMODIAQUINECoarsucamMalariaPM_L_0164ATAQ EASYNCT00316329
    ARTESUNATE + AMODIAQUINECoarsucamMalariaARAMF_L_02661NANCT00699920
    ARTESUNATE + AMODIAQUINECoarsucamMalariaARAMF_C_05370NANCT01378286
    ARTESUNATE + AMODIAQUINECoarsucamMalariaARAMF_L_04314NANCT01023399
    ATACIGUATNot marketedPain, NeuropathicDFI10569SERENEATINCT00799656
    ATACIGUATNot marketedPeripheral Arterial DiseaseDFI6174ACCELANCT00443287
     

     

    References:

    • *These study results were previously posted on GenzymeClinicalResearch.com
     
     

    © Sanofi 2004-2017 - All rights reserved - Update: December 09, 2016

    • Site complies with W3C WCAG 2.0 (new window, in english)